Hepatitis B immune globulin - OMRIX BiopharmaceuticalsAlternative Names: HBIG - OMRIX Biopharmaceuticals; Human-specific anti-hepatitis B immunoglobulin (anti HBsAg) - OMRIX Biopharmaceuticals; Omri-Hep-B; Omri-Hep-B IV
Latest Information Update: 13 Jul 2010
At a glance
- Originator OMRIX Biopharmaceuticals
- Class Antivirals; Immunoglobulins
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hepatitis B
Most Recent Events
- 30 Dec 2008 OMRIX Biopharmaceuticals has been acquired by Johnson and Johnson